CCND1 and adenocarcinoma: Several phase 1 and 2 studies have implicated cyclin D1 in esophageal malignancy, and overexpression of cyclin D1 protein has been reported in up to 64% of adenocarcinomas and associated Barrett epithelia 110,111.